Production, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic Variation.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27695087)

Published in PLoS One on October 03, 2016

Authors

Bart W Faber1, Stephan Hellwig2, Sophie Houard3, Nicolas Havelange3, Jürgen Drossard2, Hubert Mertens2, Alexander Croon2, Robin Kastilan2, Richard Byrne4, Nicole van der Werff1, Marjolein van der Eijk1, Alan W Thomas1, Clemens H M Kocken1, Edmond J Remarque1

Author Affiliations

1: Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, The Netherlands.
2: Fraunhofer IME, Aachen, Germany.
3: European Vaccine Initiative, Universitätsklinikum Heidelberg, Heidelberg, Germany.
4: Nova Laboratories Ltd., Martin House, Gloucester Crescent, Wigston, Leicester, United Kingdom.

Associated clinical trials:

Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults (AMA1-DiCo) | NCT02014727

Articles cited by this

Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem (1996) 45.70

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 10.79

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med (2012) 6.64

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun (2002) 4.02

A field trial to assess a blood-stage malaria vaccine. N Engl J Med (2011) 3.20

Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine (1998) 3.16

Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen. Parasite Immunol (1988) 2.79

Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol (2008) 2.63

High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect Immun (2002) 2.61

Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization. J Biol Chem (1998) 2.44

Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol (2003) 2.32

Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med (2013) 2.24

Altitudinal changes in malaria incidence in highlands of Ethiopia and Colombia. Science (2014) 1.92

A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun (2008) 1.73

Protein secretion in Pichia pastoris and advances in protein production. Appl Microbiol Biotechnol (2011) 1.61

Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One (2008) 1.56

Fine mapping of an epitope recognized by an invasion-inhibitory monoclonal antibody on the malaria vaccine candidate apical membrane antigen 1. J Biol Chem (2006) 1.47

Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity. PLoS One (2009) 1.45

A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine (2005) 1.45

Structural and functional insights into the malaria parasite moving junction complex. PLoS Pathog (2012) 1.44

First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine (2013) 1.16

Improved production of recombinant ovine interferon-tau by mut(+) strain of Pichia pastoris using an optimized methanol feed profile. Biotechnol Prog (2003) 1.12

Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria. Proc Natl Acad Sci U S A (2014) 1.12

Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris. Vaccine (2008) 1.10

Temperature limited fed-batch technique for control of proteolysis in Pichia pastoris bioreactor cultures. Microb Cell Fact (2003) 1.07

Analysis and control of proteolysis of a fusion protein in Pichia pastoris fed-batch processes. J Biotechnol (2003) 1.06

Causes of proteolytic degradation of secreted recombinant proteins produced in methylotrophic yeast Pichia pastoris: case study with recombinant ovine interferon-tau. Biotechnol Bioeng (2005) 1.04

Characterization of recombinant barley oxalate oxidase expressed by Pichia pastoris. J Biol Inorg Chem (2001) 1.04

Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT™ protects against blood-stage challenge in rhesus macaques. PLoS One (2011) 1.01

Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines. Infect Immun (2013) 1.00

An optimized fermentation process for high-level production of a single-chain Fv antibody fragment in Pichia pastoris. Protein Expr Purif (2004) 1.00

Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. J Infect Dis (2016) 0.91

A proteomic analysis of the Pichia pastoris secretome in methanol-induced cultures. Appl Microbiol Biotechnol (2011) 0.90

High-level expression of Candida parapsilosis lipase/acyltransferase in Pichia pastoris. J Biotechnol (2004) 0.84

Production of carcinoembryonic antigen (CEA) N-A3 domain in Pichia pastoris by fermentation. Biotechnol Appl Biochem (1999) 0.84

Optimization of the production of gurmarin, a sweet-taste-suppressing protein, secreted by the methylotrophic yeast Pichia pastoris. Appl Microbiol Biotechnol (2012) 0.82

Expression of xyloglucan endotransglycosylases of Gerbera hybrida and Betula pendula in Pichia pastoris. J Biotechnol (2007) 0.79

Cell bank characterization and fermentation optimization for production of recombinant heavy chain C-terminal fragment of botulinum neurotoxin serotype E (rBoNTE(H(c)): antigen E) by Pichia pastoris. J Biotechnol (2006) 0.79

A multi-bioreactor system for optimal production of malaria vaccines with Pichia pastoris. Biotechnol J (2011) 0.77

Designing a fully automated multi-bioreactor plant for fast DoE optimization of pharmaceutical protein production. Biotechnol J (2013) 0.77